Coronary side-effect potential of current and prospective antimigraine drugs

Circulation

Volumn 98, Issue 1, 1998, Pages 25-30

  MaassenVanDenBrink, Antoinette ^c   Reekers, Marije ^c   Bax, Willem A ^b   Ferrari, Michel D ^a   Saxena, Pramod R ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b EEMLAND HOSPITAL   (Netherlands)

^c Erasmus University Rotterdam ^*

Author keywords

Antimigraine drugs; Coronary disease; Migraine; Pharmacology; Vasoconstriction

Indexed keywords

ANTIMIGRAINE AGENT; AVITRIPTAN; DIHYDROERGOTAMINE; ERGOTAMINE; METHYLERGOMETRINE; METHYSERGIDE; NARATRIPTAN; POTASSIUM CHLORIDE; PROSTAGLANDIN F2 ALPHA; RIZATRIPTAN; SUBSTANCE P; SUMATRIPTAN; ZOLMITRIPTAN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENCY; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; ISOLATED ARTERY; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0001821138     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.1.25     Document Type: Article

References (49)

1. Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. Eur Neurol. 1991;31:339-344.
2. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
3. Visser WH, de Vriend RHM, Jaspers NMWH, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology. 1996;47:46-51.
4. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet. 1994;344:985-986.
5. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993;87:401-405.
6. 2 receptor activation. Eur J Pharmacol. 1989;161:91-94.
7. Chester AH, O'Neil GS, Yacoub MH. Sumatriptan and ischaemic heart disease. Lancet. 1993;341:1419-1420.
8. Bax WA, Saxena PR. Sumatriptan and ischaemic heart disease. Lancet. 1993;341:1420. Letter.
9. Yasue H, Omote S, Takizawa A, Nagao M. Acute myocardial infarction induced by ergotamine tartrate: possible role of coronary arterial spasm. Angiology. 1981;32:414-418.
10. Galer BS, Lipton RB, Solomon S, Newman LC, Spierings ELH. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache. 1991;31:446-450.
11. Koh KK, Roe IH, Lee MM, Cho SK, Kim SS. Variant angina complicating ergot therapy of migraine. Chest. 1994;105:1259-1260.
12. Ottervanger JP, Paalman HJA, Boxma GL, Stricker BHC. Transmural myocardial infarction with sumatriptan. Lancet. 1993;341:861-862.
13. O'Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology. 1995;45:2274-2276.
14. Kelly KM. Cardiac arrest following use of sumatriptan. Neurology. 1995;45:1211-1213.
15. 1D receptor agonists. Expert Opinion in Investigational Drugs. 1996;5:581-593.
16. Bredberg U, Eyjolfdottir GS, Paalzow L, Tfelt-Hansen P, Tfelt-Hansen V. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol. 1986;30:75-77.
17. Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, Humphrey PP. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia. 1997;17:145-152.
18. 1D receptor agonists. Neurology. 1997;48(suppl 3):S21-S24.
19. Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J, Honey AC, Giles H, Moncada S. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997;121:157-164.
20. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, Dutch/US Rizatriptan Study Group. Rizatriptan vs sumatriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Arch Neurol. 1996;53:1132-1137.
21. Goldstein J, Ryan RE Jr, Elkind AH. A double-blind trial of BMS-180048 at 75 mg, 150 mg and 200 mg in the acute treatment of migraine headaches. Fund Neurol. 1996;11:147. Abstract.
22. 1Dβ receptors. Circulation. 1994;90:1141-1153.
23. MaassenVanDenBrink A, Bax WA, Ferrari MD, Zijlstra FJ, Bos E, Saxena PR. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol. 1996;119:855-862.
24. Chester AH, Martin GR, Bodelsson M, Arneklo-Nobin B, Tadjkarimi S, Törnebrandt K, Yacoub MH. 5-Hydroxytryplamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc Res. 1990;24:932-937.
25. Golino P, Piscione F, Willerson JT, Cappelli-Bigazzi M, Focaccio A, Villari B, Indolfi C, Russolillo E, Condorelli M, Chiariello M. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991;324:641-648.
26. McFadden EP, Bauters C, Lablanche JM, Leroy F, Clarke JG, Henry M, Schandrin C, Davies GJ, Maseri A, Bertrand ME. Effect of ketanserin on proximal and distal coronary constrictor responses to intracoronary infusion of serotonin in patients with stable angina, patients with variant angina, and control patients. Circulation. 1992;86:187-195.
27. Ferro A, Longmore J, Hill RG, Brown MJ. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery In vitro. Br J Clin Pharmacol. 1995;40:245-251.
28. 1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol. 1996;42:431-441.
29. Niimi Y, Azuma H, Hirakawa K. Repeated endothelial removal augments intimal thickening and attenuates EDRF release. Am J Physiol. 1994;266: H1348-H1356.
30. Wennmalm A. Endothelial nitric oxide and cardiovascular disease. J Intern Med. 1994;235:317-327.
31. MaassenVanDenBrink A, Ramrattan NR, Bax WA, Ferrari MD, Saxena PR. Human isolated coronary artery contraction to sumatriptan is inversely related to age and positively related to endothelial functional integrity. Cephalalgia. 1997;17:244. Abstract.
32. 3 positron emission tomography. Neurology. 1997;48:1542-1550.
33. Winbury MM, Howe BB. Stenosis: regional myocardial ischemia and reserve. In: Winbury MM, Abiko Y, eds. Ischaemic Myocardium and Antianginal Drugs. New York, NY: Raven Press; 1979:55-76.
34. 2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation. 1993;87:874-880.
35. 1D receptor agonist effects of dihydroergotamine. In: Olesen J, Moskowitz MA, eds. Experimental Headache Models. Philadelphia, Pa:: Lippincott-Raven; 1995:163-167.
36. Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther. 1985;37:29-35.
37. Östergaard JR, Mikkelsen E, Voldby B. Effects of 5-hydroxytryptamine and ergotamine on human superficial temporal artery. Cephalalgia. 1981;1:223-228.
38. Tfelt-Hansen P, Saxena PR, Ferrari MD, Ergot alkaloids. In: de Wolff FA, ed. Handbook of Clinical Neurology, Vol. 21 (65): Intoxications of the Nervous System, Part II. Amsterdam, Netherlands: Elsevier Science BV; 1995:61-78.
39. Maurer G, Frick W. Elucidation of the structure and receptor binding studies of the major primary metabolite of dihydroergotamine in man. Eur J Clin Pharmacol. 1984;26:463-470.
40. Scott AK. Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet 1994;27:337-344.
41. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol. 1996;41:141-147.
42. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Pharmacol. 1995;47:543-548.
43. Kempsford RD, Bailie P, Fuseau E. Oral naratriptan tablets (2.5 mg-10 mg) exhibit dose-proportional pharmacokinetics. Neurology. 1997; 48:A66. Abstract.
44. Kramer MS, Matzura-Wolfe D, Getson A, Polis A, Reines SA. Placebo controlled, double-blind study of rizatriptan in multiple attacks of acute migraine. Neurology. 1997;48:A68-A69. Abstract.
45. 1D agonist. Br J Clin Pharmacol. 1997;43: 49-54.
46. Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, Wilkinson M, Sweet RM, Klein KB. A multi-center, double-blind, placebo-controlled, dose-range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache. 1995;35:292. Abstract.
47. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet. 1985;10:334-352.
48. Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol. 1986;30:331-334.
49. Little PJ, Jennings GL, Skews H, Bobik A. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol. 1982;13:785-790.